# DCVAC/OvCa After Standard-of-care Chemotherapy in Women With Relapse of Platinum-sensitive Epithelial Ovarian Cancer

> **NCT03657966** · PHASE2 · COMPLETED · sponsor: **SOTIO a.s.** · enrollment: 33 (actual)

## Conditions studied

- Ovarian Cancer Recurrent

## Interventions

- **BIOLOGICAL:** DCVAC/OvCa
- **DRUG:** Standard of Care Chemotherapy

## Key facts

- **NCT ID:** NCT03657966
- **Lead sponsor:** SOTIO a.s.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-23
- **Primary completion:** 2020-11-11
- **Final completion:** 2021-02-25
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2021-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03657966

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03657966, "DCVAC/OvCa After Standard-of-care Chemotherapy in Women With Relapse of Platinum-sensitive Epithelial Ovarian Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03657966. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*